Mito.Tech Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Private

  • Employees
  • 6

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 2

Mito.Tech General Information

Description

Operator of a biotechnology platform intended to develop mitochondria-focused treatments for obesity and metabolic dysfunction-associated steatohepatitis (MASH). The company offers small-molecule drug candidates designed to increase cellular energy expenditure, enabling pharmaceutical companies and healthcare researchers to investigate potential treatments for metabolic diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 9, Jerdan Place
  • Suite 144
  • London SW6 1BE
  • England, United Kingdom
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 9, Jerdan Place
  • Suite 144
  • London SW6 1BE
  • England, United Kingdom

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Mito.Tech Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC 15-Oct-2025 Completed Clinical Trials - Phase 1
2. Accelerator/Incubator Completed Clinical Trials - Phase 1
1. Later Stage VC 28-Aug-2018 $17M $17M Completed Generating Revenue
To view Mito.Tech’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Mito.Tech Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biotechnology platform intended to develop mitochondria-focused treatments for obesity and metabolic dysfu
Drug Discovery
London, United Kingdom
6 As of 2026

King Of Prussia, PA
 

Princeton, NJ
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Mito.Tech Competitors (19)

One of Mito.Tech’s 19 competitors is CSL Behring, a Corporation company based in King Of Prussia, PA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CSL Behring Corporation King Of Prussia, PA
Bristol-Myers Squibb Corporation Princeton, NJ
Genentech Formerly VC-backed South San Francisco, CA
Oxcia AB (publ) Corporation Stockholm, Sweden
Merck & Co. Corporation Rahway, NJ
You’re viewing 5 of 19 competitors. Get the full list »

Mito.Tech Patents

Mito.Tech Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260217746-A1 Crystalline forms of antioxidant compound Pending 16-Aug-2024
AU-2025241722-A1 Treatment and prevention of obesity using a combination of mitochondrial uncouplers and glucagon-like peptide-1 receptor agonists Pending 18-Mar-2024
WO-2025196507-A1 Treatment and prevention of obesity using a combination of mitochondrial uncouplers and glucagon-like peptide-1 receptor agonists Pending 18-Mar-2024
US-12077553-B1 Crystalline form of antioxidant compound Active 09-Nov-2023
AU-2024378319-A1 Crystalline forms of antioxidant compound Pending 09-Nov-2023 C07F9/5442
To view Mito.Tech’s complete patent history, request access »

Mito.Tech Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Mito.Tech Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
Essex Bio-technology Corporation Minority
MSU Science Park Accelerator/Incubator
To view Mito.Tech’s complete investors history, request access »

Mito.Tech FAQs

  • When was Mito.Tech founded?

    Mito.Tech was founded in 2010.

  • Where is Mito.Tech headquartered?

    Mito.Tech is headquartered in London, United Kingdom.

  • What is the size of Mito.Tech?

    Mito.Tech has 6 total employees.

  • What industry is Mito.Tech in?

    Mito.Tech’s primary industry is Drug Discovery.

  • Is Mito.Tech a private or public company?

    Mito.Tech is a Private company.

  • What is Mito.Tech’s current revenue?

    The current revenue for Mito.Tech is .

  • How much funding has Mito.Tech raised over time?

    Mito.Tech has raised $17M.

  • Who are Mito.Tech’s investors?

    Essex Bio-technology and MSU Science Park have invested in Mito.Tech.

  • Who are Mito.Tech’s competitors?

    CSL Behring, Bristol-Myers Squibb, Genentech, Oxcia AB (publ), and Merck & Co. are some of the 19 competitors of Mito.Tech.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process